CAG Repeat Testing of Androgen Receptor Polymorphism: Is This Necessary for the Best Clinical Management of Hypogonadism?
July 2013
in “
The Journal of Sexual Medicine
”
Studysummary This review discusses the potential role of androgen receptor CAG repeat polymorphism testing in hypogonadism management for both sexes, but its clinical utility remains unclear and requires further investigation.
Our plain-language summary. Not medical advice or a treatment recommendation. Consult a qualified healthcare professional before changing treatment. Full disclaimer
The document reviewed the clinical relevance of CAG repeat polymorphism in the androgen receptor gene for managing hypogonadism and concluded that its role is not established in clinical practice due to unclear relationships between CAG repeat number and hypogonadal symptoms. Although it may be important for predicting treatment response and side effects, especially in obese men and postmenopausal women, current evidence does not support routine testing in clinical settings. The document also discussed AR CAG repeat polymorphism's role in prostate cancer, female hypogonadism, and neurodegenerative diseases, noting potential associations with various conditions and treatment outcomes. However, it emphasized the need for more research to confirm these findings and to develop tailored treatments based on AR polymorphism.
